info@oncologyventure.com

Abstracts on Three Pipeline Products Selected for 2018 ASCO Clinical Meeting

  Phase 1 Study of PARP Inhibitor 2X-121 Selected as Oral Presentation June 1, 2018 Hoersholm, Denmark and Cambridge, MA...